Spero Therapeutics (SPRO) Return on Equity (2017 - 2025)
Historic Return on Equity for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2025 value amounting to 1.46%.
- Spero Therapeutics' Return on Equity fell 15600.0% to 1.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.46%, marking a year-over-year decrease of 15600.0%. This contributed to the annual value of 0.9% for FY2024, which is 11900.0% down from last year.
- Per Spero Therapeutics' latest filing, its Return on Equity stood at 1.46% for Q3 2025, which was down 15600.0% from 1.61% recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Return on Equity registered a high of 0.33% during Q4 2023, and its lowest value of 2.78% during Q3 2022.
- In the last 5 years, Spero Therapeutics' Return on Equity had a median value of 0.74% in 2022 and averaged 0.82%.
- In the last 5 years, Spero Therapeutics' Return on Equity soared by 27700bps in 2023 and then plummeted by -20200bps in 2025.
- Spero Therapeutics' Return on Equity (Quarter) stood at 0.88% in 2021, then increased by 15bps to 0.74% in 2022, then skyrocketed by 145bps to 0.33% in 2023, then plummeted by -469bps to 1.23% in 2024, then dropped by -19bps to 1.46% in 2025.
- Its Return on Equity was 1.46% in Q3 2025, compared to 1.61% in Q2 2025 and 1.75% in Q1 2025.